PTPRT Could Be a Treatment Predictive and Prognostic Biomarker for Breast Cancer

Biomed Res Int. 2021 Aug 10:2021:3301402. doi: 10.1155/2021/3301402. eCollection 2021.

Abstract

The role of PTPRT in breast cancer was not comprehensively explored and well analyzed. Our study comprehensively searched available databases to analyze the clinical role of PTPRT in breast cancer. We found PTPRT was an antioncogene and could be used to distinguish different stages, age groups, molecular types, and grades for breast cancer. PTPRT might be primary resistance biomarkers for taxane, anthracycline, and ixabepilone but not be acquired resistance biomarkers. Higher PTPRT expression levels were associated with longer overall survival and recurrence-free survival. PTPRT was negatively associated with Ki67 and CDK4/6 but positively associated with BCL-2. PTPRT might be associated with cell cycle and microtubule, and tumor infiltration in B cell and macrophage cell. PTPRT could predict chemotherapy effectiveness and prognosis for breast cancer patients. PTPRT might inhibit tumor growth via disrupting the microtubule dynamics and cell cycle in breast cancer.

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor / genetics*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / genetics
  • Breast Neoplasms / pathology*
  • DNA Methylation*
  • Databases, Genetic
  • Drug Resistance, Neoplasm*
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Staging
  • Prognosis
  • Promoter Regions, Genetic
  • Receptor-Like Protein Tyrosine Phosphatases, Class 2 / genetics*
  • Survival Analysis
  • Up-Regulation*
  • Young Adult

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • PTPRT protein, human
  • Receptor-Like Protein Tyrosine Phosphatases, Class 2